Sri Krishna Pharma

Name

Sri Krishna Pharma

Legal name

Sri Krishna Pharmaceuticals Limited

Website

https://srikrishnapharma.com

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. API Manufacturing and Sales: Bulk manufacture and sale of Active Pharmaceutical Ingredients (APIs) including Paracetamol/Acetaminophen, Domperidone, Folic Acid, and other pharmaceutical intermediates. Revenue generated from selling manufactured APIs to pharmaceutical companies globally.
2. DC Granules and Finished Dosage Forms: Direct compression granules, tablets, capsules sold as finished products or in bulk. Forward integration allows offering customers greater value with blister packaging or bulk options. Products include Paracetamol, Metformin, Ibuprofen, Guaifenesin.
3. Contract Manufacturing Organization (CMO) Services: Six engagement models providing formulation development, manufacturing services, and R&D for partners. Includes generic CMO, joint development, IP-based offerings, and novel drug delivery solutions.
4. Nutraceutical Products: Sri Krishna Nutra division offers nutraceutical solutions including standard and custom formulations using advanced microencapsulation technologies for vitamins, phytonutrients, and minerals.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Sri Krishna Pharma is a vertically integrated pharmaceutical manufacturer that bulk-produces Active Pharmaceutical Ingredients (APIs) such as Paracetamol/Acetaminophen, Domperidone, Folic Acid, Meclizine, Glipizide, Glibenclamide and Furosemide, alongside direct compression (DC) granules, finished dosage forms (tablets and capsules), custom synthesized intermediates, and nutraceutical ingredients through its Sri Krishna Nutra division. The company also operates as a Contract Manufacturing Organization (CMO) offering six partnership models spanning generic CMO, joint development, branded IP-based offerings, novel drug delivery formulation, bespoke CMO with shared risk/reward, and novel R&D solutions.

Product overview

Sri Krishna Pharma is a vertically integrated pharmaceutical manufacturer offering a portfolio of products across the drug development and manufacturing value chain. The core offerings include: APIs (Active Pharmaceutical Ingredients) such as Paracetamol/Acetaminophen, Domperidone, Folic Acid, Meclizine Hydrochloride, Glipizide, and Glibenclamide; DC (Direct Compression) granules for simplified tablet manufacturing; Finished Dosage Forms (FDF) including tablets and capsules in various formats (film-coated, chewable, hard-coated); Custom synthesized intermediates; and Sri Krishna Nutra, a modern nutraceutical division. The company operates as a CMO (Contract Manufacturing Organization) offering multiple engagement models from generic manufacturing to novel drug delivery development. The products are supplied globally across 60+ countries with regulatory certifications including US FDA, EDQM, and WHO GMP.

Differentiator

Problem solved

Functional benefit

Brands

• Sri Krishna Nutra: Complete nutraceutical solutions partner delivering application focused, end-to-end solutions using advanced microencapsulation technologies for vitamins, phytonutrients, and minerals.

Products and services

• Active Pharmaceutical Ingredients (APIs) Bulk manufacture of Active Pharmaceutical Ingredients including Paracetamol/Acetaminophen, Domperidone, Folic Acid, Meclizine Hydrochloride, Glipizide, Glibenclamide/Glyburide, Furosemide, Enalapril Maleate, Metadoxine, Timonium Methyl Sulphate, and Fenoverine, supplied to pharmaceutical companies globally for use in generic and branded drug manufacturing.
• Direct Compression (DC) Granules Directly compressible granulation products manufactured at the Nacharam facility, including Paracetamol DC with 15+ excipient derivatives and combinations such as paracetamol & ibuprofen and paracetamol & caffeine. Supplied to pharmaceutical companies in Europe, Canada and Asia to simplify downstream tablet manufacturing.
• Finished Dosage Forms (Tablets and Capsules) Tablets and capsules produced at the Nacharam unit in film-coated, hard-coated and chewable formats, including products based on Paracetamol, Ibuprofen, Metformin, Aspirin, Furosemide, Naproxen, and Ciprofloxacin. Available in blister packaging or bulk for pharmaceutical customers.
• Custom Synthesized Intermediates Custom synthesized pharmaceutical intermediates manufactured at the Solapur Unit V facility, including Lasamide and Disulfonamide, supplied to pharmaceutical customers for use in API synthesis.
• Sri Krishna Nutra (Nutraceutical Solutions) Nutraceutical solutions offering using advanced microencapsulation, beadlet and hydrocolloid technologies to convert complex, water-insoluble and lipophilic actives (vitamins, phytonutrients, minerals, botanical extracts) into stable, bioavailable, application-ready ingredient formats for nutraceutical companies.
• Contract Manufacturing Organization (CMO) Services Contract manufacturing services for pharmaceutical partners across six engagement models, ranging from generic CMO for off-patent drugs, to joint development with shared margins, branded offerings using SKPL IP, novel drug delivery formulation development, bespoke CMO with risk/reward sharing, and novel R&D solutions.
• Formulation Development Services Need-based formulation development services matching bespoke solutions with customer requirements, spanning from generic CMO through to innovator novel drug delivery development, supported by an R&D division in Chennai with global collaborations.

Quantifiable outcome

• Direct compression reduces handling, capital expenditure, storage needs, and risk of product contamination for customers

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• DCAT Week 2026 ParticipantscoreOthers · 16 February 2026Sri Krishna Pharma attended DCAT Week 2026 in New York (March 23-26, 2026) to meet with industry leaders, discuss supply chain developments, strategic partnerships and emerging market opportunities.
• Akshaya Patra FoundationminorOthersCSR partnership through the Sustainability Report. Akshaya Patra Foundation works to address health, malnutrition, and quality of life issues, promoting inclusive growth.
• Isha OutreachminorOthersCSR partnership through the Sustainability Report. Isha Outreach addresses health, malnutrition, and quality of life for communities.
• Ramakrishna MathminorOthersCSR partnership through the Sustainability Report. Ramakrishna Math addresses health, malnutrition, and quality of life for communities.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Hovione: Portugal-headquartered global CDMO with a long-standing paracetamol API heritage. Comparable to Sri Krishna in API manufacturing expertise, regulatory certifications, and serving global pharma customers — but operating with a broader CDMO portfolio.
• Apotex: Canadian generic pharmaceutical manufacturer with vertically integrated API sourcing. Comparable in operating a vertically integrated generic pharma model, though at substantially larger scale and primarily retail-focused.
• Cambrex: Global small-molecule API and CDMO player. Comparable to Sri Krishna in providing small-molecule APIs and contract manufacturing services to global pharma, though with a higher CDMO mix.
• Aenova: European contract development and manufacturing organization with solid-dose and API capabilities. Comparable to Sri Krishna's CMO/FDF offering but with a primarily European customer base.
• Aurobindo Pharma: One of India's largest generic pharmaceutical manufacturers with significant API operations. Overlaps with Sri Krishna in API and FDF supply to global generics customers, though substantially larger in scale.

Direct peers

• Laurus Labs: Hyderabad-headquartered API manufacturer and CDMO with strong paracetamol and folic acid portfolios. Laurus is a direct comparable given its Indian location, API-led model, and global pharma customer base.
• Granules India: Indian vertically integrated manufacturer of APIs, DC granules, and finished dosage forms. Granules India mirrors Sri Krishna's API→DC→FDF business model and competes head-to-head in paracetamol DC granules for global generic customers.
• Divis Laboratories: Indian pure-play API manufacturer serving global generics and innovator pharma. Comparable in regulatory depth, US FDA/EDQM footprint, and small-molecule manufacturing scale.
• Ipca Laboratories: Indian API + formulation manufacturer with overlapping paracetamol, folic acid, and anti-diabetic (glimepiride/gliclazide) portfolios. Ipca competes directly in the same small-molecule therapy areas as Sri Krishna.
• SMS Pharmaceuticals: Hyderabad-based API manufacturer focused on small-molecule APIs across multiple therapy areas. SMS is comparable in scale, geography, and the commoditized-generic-API business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sri-krishna-pharmaceuticals-ltd-

Compliance17 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sri Krishna Pharma